Following the switch from gadodiamide to gadobenate dimeglumine and gadopentetate dimeglumine, and the adoption of restrictive gadolinium-based contrast agent policies, no nephrogenic systemic fibrosis (NSF) cases were observed at two university health centers, according to a study in the October issue of Radiology.